Champions Oncology Inc. (NASDAQ: CSBR) Stock Information | RedChip

Champions Oncology Inc. (NASDAQ: CSBR) Listen to this Section


$4.45
-0.0650 ( -1.44% ) 4.1K

Champions Oncology Inc is a USA based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. They derive revenue primarily from research services.

Market Data


Open


$4.45

Previous close


$4.51

Volume


4.1K

Market cap


$61.04M

Day range


$4.45 - $4.59

52 week range


$4.43 - $7.13

Insider Ownership Transactions

Total Amount Purchased: -105,460.00 | $ -468,769.70

Date Type Amount Purchased Purchaser
2023-12-26 Buy 2500.00 Mendelson Daniel Newman
2023-12-21 Buy 2100.00 Mendelson Daniel Newman
2023-12-20 Buy 5000.00 Mendelson Daniel Newman
2023-11-07 Sale -15495.00 Breitfeld Philip P.
2023-11-07 Sale -26220.00 Mendelson Daniel Newman
2023-11-07 Sale -28600.00 TOBIN SCOTT R
2023-11-07 Sale -35750.00 ACKERMAN JOEL
2023-11-07 Sale -15495.00 SIDRANSKY DAVID
2023-10-16 Buy 1500.00 Mendelson Daniel Newman
2023-10-16 Buy 5000.00 Mendelson Daniel Newman

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Jan 08, 2024
4 Insider transactions 1 Jan 08, 2024
4 Insider transactions 1 Jan 05, 2024
4 Insider transactions 1 Jan 04, 2024
4 Insider transactions 1 Dec 26, 2023
4 Insider transactions 1 Dec 21, 2023
4 Insider transactions 1 Dec 20, 2023
10-q Quarterly Reports 58 Dec 13, 2023
8-k 8K-related 14 Dec 12, 2023
4 Insider transactions 1 Nov 07, 2023

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.